GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » 12-1 Month Momentum %

Kintara Therapeutics (STU:3DMA) 12-1 Month Momentum % : -95.23% (As of Oct. 31, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-10-31), Kintara Therapeutics's 12-1 Month Momentum % is -95.23%.

The industry rank for Kintara Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

STU:3DMA's 12-1 Month Momentum % is ranked worse than
97.93% of 1446 companies
in the Biotechnology industry
Industry Median: -8.55 vs STU:3DMA: -95.23

Competitive Comparison of Kintara Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Kintara Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's 12-1 Month Momentum % falls into.



Kintara Therapeutics  (STU:3DMA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics  (STU:3DMA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Kintara Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines